Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363

Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

# POLICY FOR DETERMINATION OF 'MATERIALITY' OF EVENT / INFORMATION

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363

Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

# **TABLE OF CONTENTS**

S.N.	Particulars	Page No.
1	LEGAL FRAMEWORK	3
2	OBJECTIVE	3
3	DEFINITIONS	3
4	INTERPRETATION	3
5	EVENTS WHICH ARE DEEMED TO BE MATERIAL EVENTS	4
6	EVENTS WHICH ARE DEPENDENT ON APPLICATION OF GUIDELINES FOR	4
	MATERIALITY	
7	GUIDELINES ON OCCURRENCE OF AN EVENT / INFORMATION & ITS TIMELY	5
	DISCLOSURE	
8	DISCLOSURE REQUIREMENTS FOR CERTAIN TYPES OF AGREEMENTS BINDING	5
	COMPANY	
9	AUTHORIZE KEY MANAGERIAL PERSONNEL (KMP) FOR THE PURPOSE OF	5
	DETERMINING MATERIALITY OF AN EVENT OR INFORMATION AND FOR THE	
	PURPOSE OF MAKING DISCLOSURES TO STOCK EXCHANGE	
10	DISCLOSURE	6
11	AMENDMENTS	6
12	SCOPE AND LIMITATION	6
13	DISSEMINATION OF POLICY	6
	ANNEXURE - A	7
	ANNEXURE - B	13

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363

Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

### 1. LEGAL FRAMEWORK

This Policy has been formulated in accordance with the current guidelines laid down by Securities Exchange Board of India under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations"), with respect to disclosure of material events and information.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, issued on September 2, 2015, the Board of Directors approved the "Policy for Determination of Materiality of Events or Information". This Policy has been updated based on the amendments made to Regulation 30 and Schedule III of the LODR Regulations, by way of the SEBI (Listing Obligations and Disclosure Requirements) (Second Amendment) Regulations, 2023 ("LODR Amendments") and the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123, dated July 13, 2023 ("SEBI Disclosure Circular").

The Board shall review, and if found required, may amend this Policy from time to time.

This Policy is applicable to the Company with effect from December 1, 2015, and the amended Policy is applicable to the Company w.e.f. May 26<sup>th</sup>, 2023.

### 2. OBJECTIVE

The objective of this Policy is to assist the employees of the Company in identifying potential material events or information in an objective manner that may originate at the ground level which can be promptly escalated and reported to the authorised Key Managerial Personnel or other officers of the Company, as specified in this Policy, for determining the materiality of the said event or information and for making necessary disclosure to the BSE Limited (the "Stock Exchange"). All provisions of Regulation 30 read with Schedule III of the LODR Regulations shall hereby be deemed to be incorporated in this Policy, by reference.

### 3. **DEFINITIONS**

In this Policy, unless the context otherwise requires:

- (a) "Act" means the Companies Act, 2013 and the rules framed thereunder, as amended from time to time.
- (b) "Board of Directors" or "Board") means the Board of Directors of the Company.
- (c) "Company" means Madhuveer Com 18 Network Limited.
- (d) "Key Managerial Personnel" means key managerial personnel as defined under sub-section (51) of section 2 of the Companies Act, 2013.
- (e) "LODR Regulations" means the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Last Amended 26<sup>th</sup> May, 2023
- (f) "Net Worth" shall have the meaning assigned to it in Section 2(57) of the Act;
- (g) "Policy" means this policy, as amended from time to time.
- (h) "SEBI" means the Securities and Exchange Board of India.
- (i) "Rules" means the rules made under the Act.
- (j) "Stock Exchange" means BSE Limited, where the equity shares of the Company are listed.
- (k) "Turnover" shall have the meaning assigned to it in Section 2(91) of the Act; All other words and expressions used but not defined in this Policy, shall have the same meaning as assigned to it under the LODR Regulations, the Act, the SEBI Act, 1992 ("SEBI Act") and the Securities Contracts (Regulation) Act, 1956 ("SCRA").

### 4. INTERPRETATION

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363

Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

Words and expressions used in this Policy shall have the same meanings respectively assigned to them in the following Acts, Rules and Regulations:

- (a) The Companies Act, 2013 or the Rules framed thereunder;
- (b) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 "SEBI LODR".
- (c) Indian Accounting Standards, as amended from time to time.

### 5. EVENTS WHICH ARE DEEMED TO BE MATERIAL EVENTS

The Company shall disclose all such events which are specified in Para A of Part A of Schedule III of the LODR Regulations (as applicable from time to time) ("Para A Events") without any application of the guidelines for materiality as specified in sub-regulation (2) of Regulation 30 of the LODR Regulations. Details to be provided to the Stock Exchanges while disclosing Para A Events shall be in compliance with the requirements of the SEBI Disclosure Circular. (appended herewith as Annexure-A)

### 6. EVENTS WHICH ARE DEPENDENT ON APPLICATION OF GUIDELINES FOR MATERIALITY

The Company shall disclose all such material events or information pertaining to itself or to its subsidiary(ies), specified in Para B of Part A of Schedule III of the LODR Regulations ("Para B Events") subject to application of guidelines for materiality, as set out under the LODR Regulations (appended herewith as Annexure-B).

### **GUIDELINES FOR DETERMINING MATERIALITY OF EVENTS OR INFORMATION:**

Quantitative criteria would be calculated based on audited consolidated financial statements and would mean the omission of an event/ information whose value involved or the expected impact in terms of value, exceeds the lower of the following:

- (a) 2% (two per cent) of consolidated turnover, as per the last audited consolidated financial statements of the Company; or
- (b) 2% (two per cent) of consolidated net worth as per the last audited consolidated financial statements of the Company (except in case the arithmetic value of the net worth is negative)); or
- (c) 5% (five percent) of average of absolute value of consolidated profit or loss after tax for last 3 years, as per the last 3 (three) audited consolidated financial statements of the Company.

In terms of the SEBI Disclosure Circular, if the average of absolute value of profit or loss is required to be considered by disregarding the 'sign' (positive or negative) that denotes such value as the said value / figure is required only for determining the threshold for 'materiality' of the event and not for any commercial consideration.

The details to be provided to the Stock Exchange while disclosing Para B Events shall be in compliance with the requirements of the SEBI Disclosure Circular.

For the avoidance of doubt, it is clarified that if the objective materiality threshold is not met, an event or information may be treated as being material if in the opinion of the Board of the Company, the event or information is considered material.

Qualitative criteria would mean an event/information:

(a) the omission of an event or information, which is likely to result in discontinuity or alteration of event or information already available publicly; or

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363

Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

- (b) the omission of an event or information is likely to result in significant market reaction if the said omission came to light at a later date; or
- (c) any other event/information may be treated as being material if in the opinion of the Board of directors of Company, the event / information is considered material.

# 7. GUIDELINES ON OCCURRENCE OF AN EVENT / INFORMATION & ITS TIMELY DISCLOSURE

The occurrence of material event/information would be either by the Company's own accord or not in the hands of the Company. It can be categorized as under:

- (a) depends upon the stage of discussion, negotiation or approval; and
- (b) in case of natural calamities, disruptions etc., it would depend upon the timing when the company became aware of the event/information.

Some events/information can be said to have occurred upon receipt of approval of Board of Directors, e.g., further issue of capital by rights issuance and in certain events/information after receipt of approval of both i.e., Board of Directors and shareholders.

However, considering the price sensitivity involved, for certain events e.g., decision on declaration of dividends etc., disclosure shall be made on receipt of approval of the event by the Board of Directors, pending shareholder's approval.

Some events/information can be said to have occurred when the Company becomes aware of the events/information, or as soon as, an officer of the entity has, or ought to have reasonably come into possession of the information in the course of the performance of his duties.

The term 'officer' shall have the same meaning as defined under the Act and shall also include Promoter of the Company

# 8. DISCLOSURE REQUIREMENTS FOR CERTAIN TYPES OF AGREEMENTS BINDING COMPANY

All the shareholders, promoters, promoter group entities, related parties, directors, key managerial personnel and employees of a listed entity or of its holding, subsidiary and associate company, who are parties to the agreements specified in clause 5A of para A of part A of schedule III to these regulations, shall inform the Company about the agreement to which the Company is not a party, within two working days of entering into such agreements or signing an agreement to enter into such agreements:

Provided that for the agreements that subsist as on the date of notification of clause 5A to Para A of part A of schedule III, the parties to the agreements shall inform the Company, about the agreement to which the Company is not a party and the listed entity shall in turn disclose all such subsisting agreements to the Stock Exchange and on its website within the timelines as specified by the Board.

# 9. AUTHORIZE KEY MANAGERIAL PERSONNEL (KMP) FOR THE PURPOSE OF DETERMINING MATERIALITY OF AN EVENT OR INFORMATION AND FOR THE PURPOSE OF MAKING DISCLOSURES TO STOCK EXCHANGE

In terms of Regulation 30(5) of the Listing Regulations, the board of directors of the listed entity shall authorize one or more Key Managerial Personnel for the purpose of determining materiality of an event or information and for the purpose of making disclosures to stock exchange under this regulation and the contact details of such personnel shall be also disclosed to the stock exchange and as well as on the listed entity's website.

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363

Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

The following KMPs are hereby severally authorized by Board of Directors for the purpose of determining materiality of an event or information and for the purpose of making disclosures to Stock Exchange ("Authorized Person(s)"):

- 1) Mr. KALPAN JASHMINKUMAR SHETH, Chairman & Managing Director
- 2) Ms. DIVYA RATHI, Company Secretary
- 3) Mr. PUNITKUMAR JAVAHARLAL BHAVSAR, Chief Financial Officer

Details of above KMPs shall be also disclosed to the Stock Exchange and as well as on the Company's website.

The materiality of events outlined above are indicative in nature. There may be a likelihood of some unforeseen events emerging due to the prevailing business scenario from time to time. Hence, the relevant Authorized Person should exercise his/her own judgement while assessing the materiality of events associated with the Company.

In case the relevant Authorized Person perceives any doubt regarding materiality he/she may consult Chairman or any other Director before disclosing the information to the Stock Exchange.

### 10. DISCLOSURE

All events/information identified as material in line with the regulation and under this Policy shall be disclosed as soon as reasonably possible and in any case not later than the following:

- i. For all material events/ information for which decision is taken in a Board meeting within 30 (thirty) minutes from the closure of the board meeting;
- ii. For all material events/ information emanating from within the Company within 12 (twelve) hours from the occurrence of the event or information;
- iii. For all material events/ information relating to the Company but emanating from outside the Company within 24 (twenty-four) hours from the occurrence of the event or information.
  - a) In case the disclosure is made after the stipulated timeline, the Company shall provide an explanation for the delay along with the disclosure.
  - b) The Company shall disclose all further material developments with respect to the disclosures referred to in this Policy on a regular basis, till the event is resolved / closed, with relevant explanations.

### 11. AMENDMENTS

The Board may subject to the applicable laws amend any provision(s) or substitute any of the provision(s) with the new provision(s) or replace the Policy entirely with a new Policy. However, no such amendment or modification shall be inconsistent with the applicable provisions of any law for the time being in force, and this Policy does not, and shall not, in any manner dilute any of the requirements set out under Regulation 30 read with Schedule III of the LODR Regulations.

### 12. SCOPE AND LIMITATION

In the event of any conflict between the provisions of this Policy and the LODR Regulations, as amended from time to time, the LODR Regulations shall prevail over this Policy and the part(s) so repugnant shall be deemed to severed from the Policy and the rest of the Policy shall remain in force.

# 13. DISSEMINATION OF POLICY

This Policy shall be hosted on the website of the Company.

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363

Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

### **ANNEXURE-A**

Events which shall be disclosed without any application of the guidelines for materiality as specified in subregulation (4) of regulation (30) of the Listing Regulations:

1. Acquisition(s) (including agreement to acquire), Scheme of Arrangement (amalgamation, merger, demerger or restructuring), sale or disposal of any unit(s), division(s), whole or substantially the whole of the undertaking(s) or subsidiary of the listed entity, sale of stake in associate company of the listed entity or any other restructuring.

Explanation (1) - For the purpose of this sub-para, the word 'acquisition' shall mean, -

- (i) acquiring control, whether directly or indirectly; or,
- (ii) acquiring or agreeing to acquire shares or voting rights in, a company, whether directly or indirectly, such that -
  - (a) the listed entity holds shares or voting rights aggregating to five per cent or more of the shares or voting rights in the said company; or
  - (b) there has been a change in holding from the last disclosure made under sub-clause (a) of clause (ii) of the Explanation to this sub-para and such change exceeds two per cent of the total shareholding or voting rights in the said company; or
  - (c) the cost of acquisition or the price at which the shares are acquired exceeds the threshold specified in sub-clause (c) of clause (i) of sub-regulation (4) of regulation 30.

Explanation (2)- For the purpose of this sub-paragraph, "sale or disposal of subsidiary" and "sale of stake in associate company" shall include-

- (i) an agreement to sell or sale of shares or voting rights in a company such that the company ceases to be a wholly owned subsidiary, a subsidiary or an associate company of the listed entity; or
- (ii) an agreement to sell or sale of shares or voting rights in a subsidiary or associate company such that the amount of the sale exceeds the threshold specified in sub-clause (c) of clause (i) of sub-regulation (4) of regulation 30.

Explanation (3)- For the purpose of this sub-paragraph, "undertaking" and "substantially the whole of the undertaking" shall have the same meaning as given under section 180 of the Companies Act, 2013.

- 2. Issuance or forfeiture of securities, split or consolidation of shares, buyback of securities, any restriction on transferability of securities or alteration in terms or structure of existing securities including forfeiture, reissue of forfeited securities, alteration of calls, redemption of securities etc.
- 3. New Rating(s) or Revision in Rating(s).
- 4. Outcome of Meetings of the board of directors: The listed entity shall disclose to the Exchange(s), within 30 minutes of the closure of the meeting, held to consider the following:
  - (a) dividends and/or cash bonuses recommended or declared or the decision to pass any dividend and the date on which dividend shall be paid/dispatched;
  - (b) any cancellation of dividend with reasons thereof;
  - (c) the decision on buyback of securities;
  - (d) the decision with respect to fund raising proposed to be undertaken
  - (e) increase in capital by issue of bonus shares through capitalization including the date on which such bonus shares shall be credited/dispatched;

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363

Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

- (f) reissue of forfeited shares or securities, or the issue of shares or securities held in reserve for future issue or the creation in any form or manner of new shares or securities or any other rights, privileges or benefits to subscribe to;
- (g) short particulars of any other alterations of capital, including calls;
- (h) financial results;
- (i) decision on voluntary delisting by the listed entity from stock exchange(s):

Provided that in case of board meetings being held for more than one day, the financial results shall be disclosed within thirty minutes of end of the meeting for the day on which it has been considered.

- 5. Agreements (viz. shareholder agreement(s), joint venture agreement(s), family settlement agreement(s) (to the extent that it impacts management and control of the listed entity), agreement(s)/treaty(ies)/contract(s) with media companies) which are binding and not in normal course of business, revision(s) or amendment(s) and termination(s) thereof.
- 5A Agreements entered into by the shareholders, promoters, promoter group entities, related parties, directors, key managerial personnel, employees of the listed entity or of its holding, subsidiary or associate company, among themselves or with the listed entity or with a third party, solely or jointly, which, either directly or indirectly or potentially or whose purpose and effect is to, impact the management or control of the listed entity or impose any restriction or create any liability upon the listed entity, shall be disclosed to the Stock Exchanges, including disclosure of any rescission, amendment or alteration of such agreements thereto, whether or not the listed entity is a party to such agreements:

Provided that such agreements entered into by a listed entity in the normal course of business shall not be required to be disclosed unless they, either directly or indirectly or potentially or whose purpose and effect is to, impact the management or control of the listed entity or they are required to be disclosed in terms of any other provisions of these regulations.

Explanation: For the purpose of this clause, the term "directly or indirectly" includes agreements creating obligation on the parties to such agreements to ensure that listed entity shall or shall not act in a particular manner.

6. Fraud or defaults by a listed entity, its promoter, director, key managerial personnel, senior management or subsidiary or arrest of key managerial personnel, senior management, promoter or director of the listed entity, whether occurred within India or abroad:

For the purpose of this sub-paragraph:

- (j) 'Fraud' shall include fraud as defined under Regulation 2(1)(c) of Securities and Exchange Board of India (Prohibition of Fraudulent and Unfair Trade Practices relating to Securities Market) Regulations, 2003
- (k) 'Default' shall mean non-payment of the interest or principal amount in full on the date when the debt has become due and payable.

Explanation 1- In case of revolving facilities like cash credit, an entity would be considered to be in 'default' if the outstanding balance remains continuously in excess of the sanctioned limit or drawing power, whichever is lower, for more than thirty days.

Explanation 2- Default by a promoter, director, key managerial personnel, senior management, subsidiary shall mean default which has or may have an impact on the listed entity.

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363

Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

- 7. Change in directors, key managerial personnel (Managing Director, Chief Executive Officer, Chief Financial Officer, Company Secretary etc.), senior management, Auditor and Compliance Officer.
- (7A) In case of resignation of the auditor of the listed entity, detailed reasons for resignation of auditor, as given by the said auditor, shall be disclosed by the listed entities to the stock exchanges as soon as possible but not later than twenty-four hours of receipt of such reasons from the auditor.
- (7B) Resignation of independent director including reasons for resignation: In case of resignation of an independent director of the listed entity, within seven days from the date of resignation, the following disclosures shall be made to the stock exchanges by the listed entities:
  - i. The letter of resignation along with detailed reasons for the resignation as given by the said director
  - (ia). Names of listed entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any.
  - ii. The independent director shall, along with the detailed reasons, also provide a confirmation that there is no other material reasons other than those provided.
  - iii. The confirmation as provided by the independent director above shall also be disclosed by the listed entities to the stock exchanges along with the disclosures as specified in sub-clause (i) above.

(7C) In case of resignation of key managerial personnel, senior management, Compliance Officer or director other than an independent director; the letter of resignation along with detailed reasons for the resignation as given by the key managerial personnel, senior management, Compliance Officer or director shall be disclosed to the stock exchanges by the listed entities within seven days from the date that such resignation comes into effect.

(7D) In case the Managing Director or Chief Executive Officer of the listed entity was indisposed or unavailable to fulfil the requirements of the role in a regular manner for more than forty five days in any

- 8. Appointment or discontinuation of share transfer agent.
- 9. Resolution plan/ Restructuring in relation to loans/borrowings from banks/financial institutions including the following details:
  - (a) Decision to initiate resolution of loans/borrowings;
  - (b) Signing of Inter-Creditors Agreement (ICA) by lenders;
  - (c) Finalization of Resolution Plan;
  - (d) Implementation of Resolution Plan;
  - (e) Salient features, not involving commercial secrets, of the resolution/ restructuring plan as decided by lenders.
- 10. One-time settlement with a bank.
- 11. Winding-up petition filed by any party / creditors.
- 12. Issuance of Notices, call letters, resolutions and circulars sent to shareholders, debenture holders or creditors or any class of them or advertised in the media by the listed entity.
- 13. Proceedings of Annual and extraordinary general meetings of the listed entity.
- 14. Amendments to memorandum and articles of association of listed entity, in brief.
- 15. (a) Schedule of analysts or institutional investors meet and presentations made by the listed entity to analysts or institutional investors.
  - Explanation: For the purpose of this clause 'meet' shall mean group meetings or group conference calls conducted physically or through digital means.

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363

Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

- (b) Audio or video recordings and transcripts of post earnings/quarterly calls, by whatever name called, conducted physically or through digital means, simultaneously with submission to the recognized stock exchange(s), in the following manner:
- (i) the presentation and the audio/video recordings shall be promptly made available on the website and in any case, before the next trading day or within twenty-four hours from the conclusion of such calls, whichever is earlier;
- (ii) the transcripts of such calls shall be made available on the website within five working days of the conclusion of such calls:

The requirement for disclosure(s) of audio/video recordings and transcript shall be voluntary with effect from April 01, 2021 and mandatory with effect from April 01, 2022.;

- 16. The following events in relation to the corporate insolvency resolution process (CIRP) of a listed corporate debtor under the Insolvency Code:
  - (a) Filing of application by the corporate applicant for initiation of CIRP, also specifying theamount of default:
  - (b) Filing of application by financial creditors for initiation of CIRP against the corporate debtor, also specifying the amount of default;
  - (c) Admission of application by the Tribunal, along with amount of default or rejection or withdrawal, as applicable;
  - (d) Public announcement made pursuant to order passed by the Tribunal under section 13 of Insolvency Code:
  - (e) List of creditors as required to be displayed by the corporate debtor under regulation 13(2)(c) of the IBBI (Insolvency Resolution Process for Corporate Persons) Regulations, 2016;
  - (f) Appointment/Replacement of the Resolution Professional;
  - (g) Prior or post-facto intimation of the meetings of Committee of Creditors;
  - (h) Brief particulars of invitation of resolution plans under section 25(2)(h) of Insolvency Code in the Form specified under regulation 36A(5) of the IBBI (Insolvency Resolution Process for Corporate Persons) Regulations, 2016;
  - (i) Number of resolution plans received by Resolution Professional;
  - (j) Filing of resolution plan with the Tribunal;
  - (k) Approval of resolution plan by the Tribunal or rejection, if applicable;
  - (I) Specific features and details of the resolution plan as approved by the Adjudicating Authority under the Insolvency Code, not involving commercial secrets, including details such as:
    - i. Pre and Post net-worth of the company;
    - ii. Details of assets of the company post CIRP;
    - iii. Details of securities continuing to be imposed on the companies' assets;
    - iv. Other material liabilities imposed on the company;
    - v. Detailed pre and post shareholding pattern assuming 100% conversion of convertible securities;
    - vi. Details of funds infused in the company, creditors paid-off;
    - vii. Additional liability on the incoming investors due to the transaction, source of such funding etc.;
    - viii. Impact on the investor revised P/E, RONW ratios etc.;

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363

Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

- ix. Names of the new promoters, key managerial persons(s), if any and their past experience in the business or employment. In case where promoters are companies, history of such company and names of natural persons in control;
- x. Brief description of business strategy.
- (m) Any other material information not involving commercial secrets.}
- (n) Proposed steps to be taken by the incoming investor/acquirer for achieving the MPS;
- (o) Quarterly disclosure of the status of achieving the MPS;
- (p) The details as to the delisting plans, if any approved in the resolution plan.
- 17. Initiation of Forensic audit: In case of initiation of forensic audit, (by whatever name called), the following disclosures shall be made to the stock exchanges by listed entities:
  - a. The fact of initiation of forensic audit along-with name of entity initiating the audit and reasons for the same, if available;
  - b. Final forensic audit report (other than for forensic audit initiated by regulatory / enforcement agencies) on receipt by the listed entity along with comments of the management, if any.
- 18. Announcement or communication through social media intermediaries or mainstream media by directors, promoters, key managerial personnel or senior management of a listed entity, in relation to any event or information which is material for the listed entity in terms of regulation 30 of these regulations and is not already made available in the public domain by the listed entity.

  Explanation "social media intermediaries" shall have the same meaning as defined under the Information Technology (Intermediary Guidelines and Digital Media Ethics Code) Rules, 2021.
- 19. Action(s) initiated or orders passed by any regulatory, statutory, enforcement authority or judicial body against the listed entity or its directors, key managerial personnel, senior management, promoter or subsidiary, in relation to the listed entity, in respect of the following:
  - (a) search or seizure; or
  - (b) re-opening of accounts under section 130 of the Companies Act, 2013; or
  - (c) investigation under the provisions of Chapter XIV of the Companies Act, 2013; along with the following details pertaining to the actions(s) initiated, taken or orders passed:
    - name of the authority;
    - II. nature and details of the action(s) taken, initiated or order(s) passed;
    - III. date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority;
    - IV. details of the violation(s)/contravention(s) committed or alleged to be committed;
    - V. impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible.
- 20. Action(s) taken or orders passed by any regulatory, statutory, enforcement authority or judicial body against the listed entity or its directors, key managerial personnel, senior management, promoter or subsidiary, in relation to the listed entity, in respect of the following:
  - (a) suspension;
  - (b) imposition of fine or penalty;

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363

Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

- (c) settlement of proceedings;
- (d) debarment;
- (e) disqualification;
- (f) closure of operations;
- (g) sanctions imposed;
- (h) warning or caution; or
- (i) any other similar action(s) by whatever name called; along with the following details pertaining to the actions(s) initiated, taken or orders passed:
  - I. name of the authority;
  - II. nature and details of the action(s) taken, initiated or order(s) passed;
  - III. date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority;
  - IV. details of the violation(s)/contravention(s) committed or alleged to be committed;
  - V. impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible.
- 21. Voluntary revision of financial statements or the report of the board of directors of the listed entity under section 131 of the Companies Act, 2013.

Reg. Office.: Office No # 812, Anand Mangal - III, Opposite Core house, Near Hirabag, Near Rajnagar Club, Ambawadi, Ahmedabad-06 | Phone - 9773151363

Email: tohealpharmachem@gmail.com CIN: L24230GJ1995PLC026244

### **ANNEXURE-B**

Events which shall be disclosed upon application of the guidelines for materiality referred sub-regulation (4) of regulation (30) of the Listing Regulations:

- 1. Commencement or any postponement in the date of commencement of commercial production or commercial operations of any unit/division.
- 2. Any of the following events pertaining to the listed entity:
  - (a) arrangements for strategic, technical, manufacturing, or marketing tie-up; or
  - (b) adoption of new line(s) of business; or
  - (c) closure of operation of any unit, division or subsidiary (in entirety or in piecemeal).
- 3. Capacity addition or product launch.
- 4. Awarding, bagging/ receiving, amendment or termination of awarded/bagged orders/contracts not in the normal course of business.
- 5. Agreements (viz. loan agreement(s) or any other agreement(s) which are binding and not in normal course of business) and revision(s) or amendment(s) or termination(s) thereof.
- 6. Disruption of operations of any one or more units or division of the listed entity due to natural calamity (earthquake, flood, fire etc.), force majeure or events such as strikes, lockouts etc.
- 7. Effect(s) arising out of change in the regulatory framework applicable to the listed entity
- 8. Pendency of any litigation(s) or dispute(s) or the outcome thereof which may have an impact on the listed entity.
- 9. Frauds or defaults by employees of the listed entity which has or may have an impact on the listed entity.
- 10. Options to purchase securities including any ESOP/ESPS Scheme.
- 11. Giving of guarantees or indemnity or becoming a surety, by whatever named called, for any third party.
- 12. Granting, withdrawal, surrender, cancellation or suspension of key licenses or regulatory approvals.
- 13. Delay or default in the payment of fines, penalties, dues, etc. to any regulatory, statutory, enforcement or judicial authority